Ingendo zitera Inyigisho: Guverinoma ishingiye kuri PCR Igihangano CTDNA Yamaha Yamaha

Vuba aha, Jama Oncology (niba 33.012) yasohoye ibisubizo by'ingenzi by'ubushakashatsi [ku ya 1. Ikibyimba cya ADNA na Stratiaction yo Gushyira mu kaga) ". Ubu bushakashatsi ninyigisho yambere yinyigisho mu isi gukoreshana ubuhanuzi bwa PCR ishingiye kuri kanseri ya CTR itangazamakuru rya kanseri ya CCR itangazamakuru rya kanseri y'ibara rya kanseri y'ibara rya kanseri y'ibara rya kanseri y'ibara rya kanseri y'ibara rya kanseri. Ubushakashatsi kandi bwasuzumwe cyane n'ikinyamakuru n'abanditsi bayo, kandi yashyizwe ku rutonde rw'impapuro z'ingenzi muri iki kibazo, kandi yashyizwe ku rutonde rw'ibanze muri iki kibazo, kandi washyizwe ahagaragara n'inyandiko y'ingenzi, kandi yashyizwe ahagaragara n'inyandiko y'ingenzi muri iki kibazo, kandi washyizwe ahagaragara na Espagne Juan Ajay Goel ukomoka muri Amerika yatumiriwe kubisubiramo. Ubushakashatsi bwatangajwe kandi na Genewewu, itangazamakuru rikomeye rya Biomedical muri Amerika.

Kanseri y'ibara (CRC) ni ikibyimba gisanzwe cya trastrointestinal mu Bushinwa. Ibirori mpuzamahanga by'ubushakashatsi kuri kanseri (IARC) byerekana ko hagaragaye imanza nshya 555.000 mu turere tw'Ubushinwa ku ya 1/3 cy'isi, hamwe nigipimo ntarengwa cyo gusimbuka kumwanya wa kabiri wa kanseri isanzwe mu Bushinwa; 286.000 bapfuye bazize ku ya 1/3 ku isi, urutonde nk'urwego rwa gatanu rusanzwe rwo kwanga kumera mu Bushinwa. Impamvu ya gatanu y'urupfu mu Bushinwa. Birashimishije kubona abarwayi basuzumwe, ibyiciro bya TNM I, II, III na IV ni 18.6%, 42,5%, 30.7% na 8.2%. Abarwayi barenga 80% bari mubyiciro byimbere kandi bitinze, naho 44% muribo bafite meterol mestase icyarimwe cyangwa ibihaha bigira ingaruka mubuzima bwabaturage bacu kandi bitera umutwaro uremereye. Dukurikije imibare y'ikigo cy'igihugu cya kanseri, impuzandengo y'igihugu ishinzwe kuvurwa kanseri y'ibara mu Bushinwa igera kuri 6.9% kugeza ku mwaka umwe. Abarwayi ba kanseri barwaye iyo ndwara kandi banatanzwe cyane mu bukungu [2].
Ibikomere bya kanseri ya kanseri birashobora kuvaho kubaga neza, kandi ikibyimba kimaze imyaka itanu kirokoka nyuma yo kubaga cyane, ariko igipimo rusange cyo kubaga gikabije, ariko umubare rusange wa retrence nyuma yo gutaka kuri 30%. Umubare w'amazu w'imyaka itanu mu baturage ba kanseri y'ibara ry'amaraso ari 90.1%, 72,6%, 53.8% na 10.4% by'iminota i, II, III na IV.
Indwara ntoya isanzwe (MRD) nimpamvu nyamukuru yijuor isubiramo nyuma yo kuvura. Mu myaka yashize, tekinoroji imenyekanisha rya MRD iteye imbere vuba, kandi ubushakashatsi bwinshi bwo kwitegereza uburemere n'ubushakashatsi bwakozwe mu gihe cya MRD ya Leta bushobora kwerekana ingaruka za kanseri y'ibara rya nyuma. Kwipimisha CTDNa bifite ibyiza byo kuba bidasobanutse, byoroshye, byihuse, hamwe na sample yo hejuru no gutsinda ibibyimba.
Amabwiriza ya NCC yo muri Amerika ya Kanseri ya Colon hamwe n'amabwiriza ya CSCO yo mu Bushinwa muri kanseri y'ibara ndetse no guteganya kwa kanseri ya CLAGNORY, no guhanura kwa Kanseri ya CHEGNOTIVER, yangize kanseri ya CHEGNOTIVES ZA CHEON, Kanseri ya Colon. Nyamara, ubushakashatsi busanzwe bwibanze kuri CTDNA ihinduka ishingiye ku ikoranabuhanga rikurikirana (Ngs), rifite uburyo bugoye, igihe kirekire, kandi gikemuke kugeza ku barwayi bo muri kanseri.
Kubijyanye na stade abarwayi kanseri ya III, bashingiye kuri NGS ishingiye kuri CTDNA DTDNA ingufu zijyanye na $ 10,000 kugirango uruzinduko rumwe kandi rusaba igihe cyo gutegereza ibyumweru bibiri. Hamwe n'ikizamini cya Metigenene Methylation muri ubu bushakashatsi, Colonaiq®, abarwayi barashobora kuba bafite igenzura rya CTDNIC bakurikiranye kuri kimwe cya cumi cy'ikiguzi hanyuma bakabona raporo mu minsi ibiri.
Dukurikije ibibazo bishya bya kanseri 560.000 mu Bushinwa buri mwaka, kanseri y'ivungizo ahanini hamwe na kanseri ya II-III (igipimo cyegeranye na 70%) zisaba byihutirwa kugenzura kanseri y'amabara buri mwaka.
Birashobora kugaragara ko ibisubizo byubushakashatsi bifite akamaro ka siyansi kandi bifatika. Binyuze mu bushakashatsi bunini bwo mu bushakashatsi bwateganijwe, byemeje ko amaraso ya PCR ashingiye ku maraso ya PCR ashobora gukoreshwa mu guhanura no gukemura ibibazo byinshi, igihe cyo gukemura ibibazo, igihe gihagije, gishoboza imiti ifatika kugira ngo izungukire abarwayi ba kanseri. Ubushakashatsi bushingiye kuri Colonaiq®, Ikizamini cya Mine-Gen Gen Methylation kuri kanseri y'amabara yatunganijwe na kuny, ikoresha igenamigambi rya Clinical ryerekeye gusuzuma hakiri kare no gusuzuma byashimangiwe no kwiga hagati.
Gastroenterology (niba33.88), Ikinyamakuru Mpuzamahanga rwa mbere mu rwego rw'indwara z'isi nyinshi muri 2021 Kanseri, kandi ibanza irasuzuma kandi irakora kandi gusaba ibishoboka byose mu gukurikirana kanseri y'amaraso.

Kugirango ushyireho kwemeza ubuvuzi bw'icyubahiro cya CTDNA mu rwego rwo Gushyira mu bikorwa, Ibyemezo bya Kanseri y'ikirere ya I-III bitandukanije) mu gihe cyo kubagwa kuvura kubizamini byamaraso ya CTDNIC.
Ubwa mbere, wasangaga ibizamini bya CTDNA bishobora guhanura ibyago byo kwisubiraho muburwayi bwa kanseri yamabara hakiri kare, haba murwego rwo hejuru no mu ntangiriro. Abarwayi beza ba CTDNA-beza bari bafite amahirwe menshi yo gusubiza nyuma yo kwisubiraho kuruta abarwayi ba CTDNative-nabi (22.0%> 4.7%). Gupima kwa CTDNative yo hambere haracyari ingaruka zahanuwe: ukwezi kumwe nyuma yo kuguriza, abarwayi beza ba CTDNA bafite byinshi basubiramo inshuro 17.5 Iri tsinda ryasanze kandi ihujwe na CTDNA na Cea ryateye imbere imikorere gato mu gutahura (AUC = 0.839) ikizamini cyonyine cyagereranijwe na CTDNA wenyine (AUC = 0.839).
Gushushanya amavuriro bihujwe nibibazo byingaruka ni ishingiro ryibibazo byihutirwa bya kanseri Ukurikije ibi, itsinda ryashyizwe ahagaragara abarwayi barwaye kanseri ya III mu matsinda atandukanye ashingiye ku isuzuma ry'ibyabaye (ibyago byinshi (T1-3N1) ndetse no kumenyekana mu mezi 3/6). Isesengura ryabonetse ko abarwayi bari mu kaga gakomeye ka CTDNA-ibyiza byagize igipimo cyo hasi niba bakiriye amezi atandatu ya adufiya; Muri subroup-yo hasi ya pompe ya CTDNA-Ibyiza, nta tandukaniro rikomeye riri hagati yo kwivuza ninzego zihangana no kuruhuka kwihangana; Mugihe abarwayi babi-babi bagiranye ubugwari bwiza kuruta abarwayi beza ba CTDNA hamwe nigihe cyo kudasubizwa mu ntangiriro (RFS); Icyiciro I hamwe ningaruka-ntoya ya kanseri ya kabiri kanseri ya kabiri ya kanseri ya CTDNA-mbi ntabwo yari isubirwamo mugihe cyimyaka ibiri; Kubwibyo, kwishyira hamwe kwa CTDNA hamwe nibiranga ubuvuzi biteganijwe kurushaho kunoza ingaruka ziterwa no guhanura neza.

Igishushanyo 1. Isesengura rya Plasma CTDNA kuri Pom1 kugirango tumenye hakiri kare kanseri yububiko
Ibindi bizamini bya CTDNIC byerekanaga ko ibyago byo kwisubiraho byari hejuru cyane ku barwayi bakurikiranye CTDna amahirwe yo kumenya hakiri kare indwara yo kwidagadura no gutabara mugihe.

Igishushanyo cya 2. Isesengura rya CTDNna rishingiye ku kintu kirekire kugirango tumenye kanseri yububiko

Ati: "Umubare munini w'ubuvuzi bw'ibitabo muri kanseri y'amabara uyobora indero, cyane cyane ibizamini bya MRDNA bishingiye kuri CTDna byerekana ubushobozi bw'ibihugu by'isosiyete yatangajwe no guharanira inyungu zishingiye ku gaciro, gufata ibyemezo bishinzwe imiti no gukurikirana.

Ibyiza byo guhitamo imigati ya ADN nkumukinnyi wa MRD ya MRD hejuru yo kumenya umwijima ni uko bidasaba ibisubizo byiza byamaraso, kandi bikaba bikoreshwa mu buryo butaziguye mu buryo bwo kwipimisha, kandi bikaba bikoreshwa mu buryo butaziguye mu buryo bwo kwipimisha, kandi bikaba bikoreshwa mu buryo butaziguye mu bigeragezo by'ibibyimba, kandi birinda ibyavuye mu maraso, kandi birinda ibisubizo by'ibinyoma, kandi bikaba bikoreshwa mu buryo butaziguye mu buryo bwo kwipimisha, kandi bikaba bikoreshwa mu buryo butaziguye mu buryo bwo kwipimisha, kandi bikaba bikoreshwa mu buryo butaziguye mu buryo bwo kwipimisha, kandi bikaba bikoreshwa mu buryo butaziguye mu kwipimisha ibinyoma, kandi bikaba bikoreshwa mu buryo butaziguye mu kwipimisha ibinyoma, kandi bikaba bikoreshwa mu buryo butaziguye mu buryo bwo kwipimisha, kandi bikaba bikoreshwa mu buryo butaziguye mu buryo bwo kwipimisha.
Ubu bushakashatsi nubundi bushakashatsi bujyanye byemeza ko icyambere cya MRDNA gishingiye ku gipimo cya CTDna aricyo kintu cyingenzi cyigenga cyo kwisubiraho I-III.
Umurima wa MRD wibasiwe vuba hamwe numubare wamashya, wunvikana cyane kandi wihariye ushingiye kuri epigetiketi (umubyimba wa ADN na Fragmentomics) hamwe na vanome yashushanyije). Turateganya ko Colonaiq ikomeje gutegura ubushakashatsi bunini bwa kavukire kandi burashobora guhinduka ikimenyetso gishya cyerekana ibizamini bya MRD bihuza. "
INGINGO
MO S ,JE L, Wang d, Han l, Zhou S, Zhou S, Dai W, Cai S, Cai S, wang R, Quo S, luo s. Jama oncol. 2023 Mata 20.
[2] "Umutwaro w'indwara ya kanseri y'amabara mu baturage b'Abashinwa: Byarahindutse mu myaka yashize? , Ikinyamakuru cy'Ubushinwa cy'igishinwa, Vol. 41, No. 10, 2020.
[3] Tarazona N, Gimeno-Valiente F, Gambardella v, et al. Igituba gikurikira-gisekuru gikurikirana cyo kuzenguruka-ikibyimba cyagutse cyo gukurikirana indwara zisanzwe zisigaye muri kanseri ya konti yaho. Ann oncol. Ugushyingo 1, 2019; 30 (11): 1804-1812.
. Kanseri ifata Ibyah 2019; 75: 1-11.